Intrasplenic Thymus Transplantation Restores Immune Function and Reverses Age-Related Involution in Preclinical Models

Researchers in China have published a landmark study in the journal Advanced Science detailing a novel method for restoring adaptive immunity: implanting thymic tissue directly into the spleen. This surgical and bioengineering approach has demonstrated a remarkable capacity to improve immune responses against viral pathogens and tumors, while effectively reversing age-related thymic involution in murine models. The findings introduce a promising alternative to conventional organ reconstruction and cellular therapies, addressing a critical bottleneck in regenerative medicine and immunology.

Background Context and The Vulnerability of the Thymus

The thymus is a specialized primary lymphoid organ situated in the upper anterior chest, just behind the sternum. Its primary biological function is the maturation of T lymphocytes, or T cells, which constitute the core cellular branch of the adaptive immune system. Within the specialized microenvironment of the thymus, precursor cells derived from bone marrow differentiate, undergo rigorous selection processes to recognize diverse foreign antigens, and acquire central self-tolerance—a vital mechanism preventing the immune system from attacking the body’s own tissues.

Despite its pivotal role in maintaining immunological health, the thymus is exceptionally vulnerable to degeneration. As humans and animals age, the organ undergoes a natural, progressive physiological decline known as thymic involution. This process involves the gradual loss and structural disorganization of functional epithelial tissue, culminating in a steep drop-off in naive T-cell production. Consequently, elderly populations experience diminished immune surveillance, leaving them increasingly susceptible to infections, autoimmune disorders, and oncological malignancies.

Beyond natural aging, the thymus can suffer acute or chronic damage from external stressors such as high-dose chemotherapy, radiotherapy, severe systemic infections, and genetic anomalies. Children born with congenital conditions like complete DiGeorge syndrome lack a functional thymus entirely, rendering them profoundly immunodeficient and vulnerable to fatal opportunistic infections. Traditional clinical interventions rely on stimulating whatever residual thymic tissue remains or utilizing engineered cellular therapies. However, when the native organ is severely degraded or completely absent, these strategies frequently fall short, highlighting an urgent need for structural organ replacement strategies.

Evolution of Transplantation Protocols

For decades, transplantation has served as a logical countermeasure against thymic loss. Cultured allogeneic or xenogeneic thymus tissue has historically been implanted into alternative anatomical sites, such as the quadriceps muscle, to re-establish a localized environment for T-cell development. While this approach has saved the lives of numerous children suffering from congenital thymic deficiencies, it faces severe biological limitations. Muscle tissue lacks the optimal vascular network, structural matrix, and cellular signaling factors required to support rapid organogenesis. Consequently, recovery via muscular implants is exceptionally slow, structurally incomplete, and frequently complicated by localized tissue necrosis.

To overcome these historical limitations, a research team hypothesized that the spleen could serve as a superior biological incubator. The spleen possesses a uniquely dense vascular network, houses a diverse population of resident immune cells, and naturally secretes essential growth factors and extracellular matrix proteins. Furthermore, the spleen exhibits specialized immunological tolerance mechanisms, making it an ideal environment for accepting and sustaining foreign (allogeneic) tissue grafts without immediate hyperacute rejection.

Experimental Methodology and Chronology

To test the efficacy of intrasplenic organogenesis, the research team structured a comprehensive multi-stage experimental timeline utilizing both immunodeficient models and naturally aged subjects.

Initially, the scientists harvested neonatal thymus tissue from donor C57BL/6J mice. Because donor thymic fragments naturally contain immature and mature T cells capable of mounting an attack against the recipient host, the team first engineered a precise culture and depletion protocol to eliminate graft-versus-host disease (GvHD) vectors while preserving the structural integrity of the stromal tissue.

In the primary model phase, young BALB/c nude mice—which possess a genetic mutation resulting in a complete absence of a functional thymus and severe T-cell deficiency—received cultured thymic fragments implanted via microsurgery into either the spleen or the quadriceps muscle.

Chronologically, the divergence in tissue development became apparent within the first fourteen days post-implantation. Splenic grafts demonstrated accelerated growth trajectories, rapidly establishing distinct cortical and medullary regions—the two essential anatomical compartments required for sequential T-cell education and maturation. By contrast, muscular control grafts remained significantly smaller, poorly organized, and frequently exhibited localized necrosis. Quantitatively, splenic grafts ultimately achieved approximately 50 percent of the mass of a normal, healthy native thymus, vastly outperforming their muscular counterparts.

Immunological Restoration and Functional Validation

Following successful anatomical engraftment, the research team monitored the systemic circulation of newly generated T cells. Circulating T-cell populations began to emerge shortly after splenic transplantation, steadily increasing in density until approximately week eight post-surgery. Although total T-cell counts did not fully match the levels observed in healthy immunocompetent controls, the qualitative recovery was striking. CD8+ cytotoxic T cells exhibited robust reconstitution, while CD4+ helper T cells stabilized at roughly half of normal control levels.

Functional assays confirmed that these regenerated T cells were not merely present in numerical terms, but were biologically active. When challenged experimentally with ovalbumin—a standard model antigen—recipient mice mounted vigorous, antigen-specific cellular responses. Crucially, this activation was mediated by the host’s own antigen-presenting cells, demonstrating functional integration with the recipient’s wider immune network. Furthermore, repertoire analysis revealed that the regenerated CD4+ T cells possessed a diverse receptor diversity, indicating successful central education capable of recognizing a wide spectrum of pathogenic threats.

Crucially, the therapeutic benefits extended beyond young, immunodeficient models to address the challenges of immunosenescence. When neonatal thymus fragments were transplanted into the spleens of naturally aged mice—specifically subjects aged 20 months—the grafts successfully grew, established organized microstructures, and drove significant improvements in naive T-cell output compared to age-matched controls.

Efficacy Against Viral Pathogens and Malignancies

To determine whether structural T-cell restoration translated into tangible clinical protection, the researchers subjected the treated models to rigorous challenge protocols involving viral infection and oncological tumor cells.

In the viral challenge phase, models were infected with vesicular stomatitis virus (VSV). Untreated immunodeficient nude mice suffered severe, unmitigated disease progression. In contrast, splenic-graft recipients rapidly deployed activated T cells, successfully controlling the viral load. By day ten post-infection, these mice exhibited significantly reduced viral retention and minimal tissue pathology, closely mirroring the clinical outcomes of healthy, immunocompetent control animals.

In oncology-focused challenges, the team evaluated tumor progression using both murine B16 melanoma cells and human HCT116 colorectal cancer cells. When inoculated with B16 melanoma, splenic-graft recipients demonstrated heavily restricted tumor growth. Their tumors were notably smaller and characterized by dense infiltrations of functional T cells, suppressing disease progression relative to untreated controls. The results were even more pronounced in the human colorectal cancer model: while aggressive tumors formed in 100 percent of untreated immunodeficient mice, tumor formation was entirely prevented in the splenic-graft recipients, demonstrating a rejection capacity equivalent to that of fully immunocompetent subjects.

Finally, to bridge the gap toward clinical translation in human medicine, the researchers evaluated the protocol using immunodeficient murine models engrafted with cryopreserved human thymic fragments and matched human hematopoietic stem cells. Human thymic tissue survived, integrated, and maintained its delicate cellular architecture within the splenic environment far more effectively than in muscular control sites. Furthermore, while thymus-only implants yielded minimal circulating human T cells, the dual transplantation of human stem cells alongside intrasplenic thymic tissue achieved robust, systemic human T-cell reconstitution.

Analytical Implications and Future Outlook

The publication of these findings marks a substantial conceptual shift in regenerative immunology. For decades, the field has struggled to find reliable biological niches capable of supporting complex thymic organogenesis outside of the thoracic cavity. By leveraging the spleen’s unique vascular architecture, matrix composition, and inherent immunological tolerance, researchers have bypassed many of the historical barriers associated with ectopic organ transplantation.

From a clinical perspective, the implications of this study are profound. If successfully translated into human medical frameworks, intrasplenic thymus transplantation could revolutionize the treatment paradigm for pediatric patients born with congenital athymia, such as those with complete DiGeorge syndrome. Furthermore, the successful reversal of age-related thymic involution in aged animal models points toward a future where immunosenescence is no longer viewed as an inevitable consequence of aging, but as a treatable condition. Restoring immune surveillance in elderly patients could fundamentally alter how modern medicine manages age-related susceptibility to infectious disease and oncological incidence.

While the study provides robust preclinical validation, translational researchers emphasize that significant hurdles remain before human clinical trials can commence. Comprehensive safety profiles, long-term stability assessments, and optimization of human tissue sourcing and cryopreservation protocols will be required. Nonetheless, this innovative methodology opens a promising avenue toward revitalizing the human immune system at its foundational source.